Quantitative Membrane Proteomics for Discovery of Actionable Drug Targets at the Surface of RAS-Driven Human Cancer Cells
Reference33 articles.
1. Hobbs GA, Der CJ, Rossman KL (2016) RAS isoforms and mutations in cancer at a glance. J Cell Sci 129(7):1287–1292
2. Gimple RC, Wang X (2019) RAS: striking at the core of the oncogenic circuitry. Front Oncol 9:965
3. Kattan WE, Hancock JF (2020) RAS function in cancer cells: translating membrane biology and biochemistry into new therapeutics. Biochem J 477(15):2893–2919
4. Canova S, Trevisan B, Abbate MI et al (2023) Novel therapeutic options for small cell lung cancer. Curr Oncol Rep
5. de Langen AJ, Johnson ML, Mazieres J et al (2023) Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet 401(10378):733–746